Clinical Trial Update: Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2) [Phase 1]

View source ↗

Summary

This Phase 1 study reports safety and tolerability findings for APN01, a recombinant human ACE2, in participants with pulmonary, cardiovascular, kidney, or canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Cardiovascular Diseases
• Kidney Diseases
• Pulmonary Diseases

Drugs mentioned

• APN01 (Recombinant human angiotensin-converting enzyme 2)

Snippet

Sponsor: Apeiron Biologics | Conditions: Pulmonary Diseases, Cardiovascular Diseases | Phase 1 | Status: COMPLETED